News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XTL Biopharmaceuticals Ltd. (XTLB) Provides Financial And Operational Update For The Second Quarter of 2014


9/3/2014 11:33:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HERZLIYA, Israel, Sept. 2, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. XTLB, +0.00% (tase:XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the three and six month periods ended June 30, 2014.

Josh Levine, CEO of XTL, stated: "There continues to be significant excitement about hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus, throughout the autoimmune research community.

Help employers find you! Check out all the jobs and post your resume.

Read at Market Watch


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES